Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Endocrinology | Family Medicine

High Cholesterol (Hyperlipidemia) Clinical Trials

A listing of High Cholesterol (Hyperlipidemia) medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.


First 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  ... Last 

Alabama

Advanced Cardiovascular, LLC
Auburn Alabama

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Alliance Clinical Research - Alabama
Birmingham Alabama 35213

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Central Alabama Research
Homewood Alabama 35209

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Heart Center Research, LLC
Huntsville Alabama

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Heart Center Research, LLC
Huntsville Alabama 35801
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

IMC Diagnostic and Medical Clinic
Mobile Alabama

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

University of South Alabama Medical Center
Mobile Alabama

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Central Alabama Research
Homewood Alabama 35209

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)

Horizon Research Group - Mobile
Mobile Alabama 36608

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)

Healthscan Research
Montgomery Alabama 36109

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)

View More »

Research Site
Birmingham Alabama 35216

A Phase 3 clinical study for patients with Hyperlipidemia

Arizona

Verde Valley Medical Center
Cottonwood Arizona

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Horizon Clinical Research Associates, PLLC
Gilbert Arizona 85295
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Mayo Clinic Arizona
Phoenix Arizona

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Cardiovascular Consultants, Limited - Phoenix
Phoenix Arizona 85015

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Cochise Clinical Research,
Sierra Vista Arizona 85635
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage, Inc./Internal Medicine Physicians
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage, Inc./Colorado Springs Health Partners - Southwest
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage, Inc./Praire Fields Family Medicine
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage, Inc./ Tatum Highlands Medical Associates, PLLC
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage, Inc./ Colorado Springs Health Partners, PC- Briargate
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Clinical Research Advantage Inc./Desert Clinical Research, LLC
Tempe Arizona 85282
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

University of Arizona
Tucson Arizona

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Eclipse Clinical Research
Tucson Arizona 85745
Updated

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Genova Clinical Research
Tucson Arizona 85704
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Radiant Research - Phoenix
Chandler Arizona 85224

High Cholesterol Research Study

Radiant Research - Scottsdale
Scottsdale Arizona 85251

Clinical Research for High Cholesterol

Radiant Research - Tucson
Tucson Arizona 85712

High Cholesterol Research Study

View More »

Research Site
Chandler Arizona 85224

A Phase 3 clinical study for patients with Hyperlipidemia

Research Site
Scottsdale Arizona 85258

A clinical research study of AMG 145 and Placebo for the treatment of Hyperlipidemia

Arkansas

Arkansas Cardiology, PA
Little Rock Arkansas

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

NEA Baptist Clinic
Jonesboro Arkansas 72401

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)

Lynn Institute of the Ozarks
Little Rock Arkansas 72205

Do you have trouble controlling your cholesterol, even on the highest dosage of medication?

Lynn Institute of the Ozarks
Little Rock Arkansas 72205

The Lynn Institute is currently conducting a clinical research study of an investigational product for high cholesterol.

View More »

Research Site
Little Rock Arkansas 72205

A Phase 3 clinical study for patients with Hyperlipidemia

California

Cardiology Consultants of Orange County
Anaheim California 92801

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Central Cardiology Medical Center
Bakersfield California

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Central Cardiology Medical Clinic
Bakersfield California 93308
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Beaver Medical Group
Banning California

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Sunrise Clinical Research - SRCR, Inc.
Bell Gardens California 90201

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)

Sunrise Clinical Research - SRCR, Inc.
Bell Gardens California 90201

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Cardiovascular Medical Group of Southern California
Beverly Hills California

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Pacific Oaks Medical Group
Beverly Hills California 90211

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Western Medical Associates of Los Angeles
Beverly Hills California 90211

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Cardiovascular Research Foundation of Southern California
Beverly Hills California 90210
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Westside Medical Associates of Los Angeles
Beverly Hills California 90211
Updated

Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Catalina Research Institute, LLC
Chino California 91710

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Med Investigations
Fair Oaks California

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

California Heart Associates
Fountain Valley California 92708

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)

California Heart Associates
Fountain Valley California 92708

Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

First 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  ... Last